View Older Stories View More Recent Stories

Jun 22, 2017 07:03AM Ayretrade, Inc. (SUMM) Presents Data From Phase 1 Clinical Programme of Ezutromid
Jun 22, 2017 07:00AM Summit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society Congress
Jun 15, 2017 07:00AM Summit Therapeutics to Participate in JMP Securities Life Sciences Conference
Jun 14, 2017 07:00AM Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2017 and Operational Progress
Jun 13, 2017 07:00AM Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2017 on 14 June 2017
Jun 5, 2017 07:00AM Summit Presents Positive New Preclinical Data on Novel CDI Antibiotic Ridinilazole at ASM Microbe 2017
May 23, 2017 07:00AM Summit Announces Key Appointments to Strengthen Research and Development Team
May 15, 2017 07:10AM Ayretrade, Inc. (SUMM) Completes Enrolment of Phase 2 Clinical Trial of Ezutromid in Patients with DMD
May 15, 2017 07:00AM Summit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMD
Apr 28, 2017 06:30PM Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit’s Ridinilazole Achieved Statistical Superiority over Vancomycin in the Treatment of C. Difficile Infecti
Mar 30, 2017 07:00AM Summit Therapeutics to Present at the Needham Healthcare Conference
Mar 29, 2017 07:00AM Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational Progress
Mar 27, 2017 07:00AM Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017
Mar 27, 2017 07:00AM Summit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients With DMD
Mar 15, 2017 07:00AM Summit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference
Feb 28, 2017 07:00AM Summit Therapeutics Recognises 10th Annual Rare Disease Day
Feb 2, 2017 07:00AM Summit Therapeutics to Participate in February Investor Conferences
Feb 1, 2017 07:00AM Summit Outlines Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Following FDA and EMA Regulatory Meetings
Jan 18, 2017 07:02AM Ayretrade, Inc. (SUMM) Appoints David Roblin as COO
Jan 18, 2017 07:00AM Summit Appoints Dr David Roblin as Chief Operating Officer and President of Research & Development
Dec 15, 2016 07:00AM Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2016 and Operational Progress
Dec 13, 2016 10:00AM Summit Therapeutics to Report Financial Results for the Third Quarter Ended 31 October 2016 on 15 December 2016
Nov 16, 2016 07:00AM Summit Enrols Patients in the United States Into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients With DMD
Oct 6, 2016 07:01AM Ayretrade, Inc. (SUMM) Announces Presentation of Preclinical DMD Data
Oct 6, 2016 07:00AM Summit Therapeutics Presents Preclinical DMD Data at the 21st International Congress of the World Muscle Society
Oct 4, 2016 07:02AM Sarepta (SRPT), Summit Therapeutics (SMMT) Enter Licensing Agreement for Utrophin Modulator Pipeline
Oct 4, 2016 07:01AM Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duc
Oct 4, 2016 07:00AM Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy
Sep 27, 2016 07:06AM Ayretrade, Inc. (SUMM) Receives FDA Rare Pediatric Disease for Ezutromid as DMD Treatment
Sep 27, 2016 07:00AM Summit Receives Rare Pediatric Disease Designation From US FDA for Ezutromid in Treatment of Duchenne Muscular Dystrophy
Sep 26, 2016 07:00AM Summit Receives Fast Track Designation From US FDA for Ezutromid in the Treatment of Duchenne Muscular Dystrophy
Sep 12, 2016 07:00AM Summit Launches Online Resource on Utrophin Modulation for the Duchenne Muscular Dystrophy Community
Sep 8, 2016 07:00AM Summit Therapeutics Reports Financial Results for the Second Quarter Ended 31 July 2016 and Operational Progress
Sep 7, 2016 07:00AM Summit Therapeutics to Present at 18th Annual Rodman & Renshaw Global Investment Conference
Sep 5, 2016 07:00AM Summit Therapeutics to Report Financial Results for the Second Quarter Ended 31 July 2016 on 8 September 2016
Aug 9, 2016 07:00AM Summit Reports Positive Phase 1 New Formulation Data and Outlines Route to Market Strategy for DMD Candidate Ezutromid
Aug 5, 2016 07:00AM Summit Therapeutics to Present at Canaccord Genuity Growth Conference
Jun 20, 2016 12:30PM Summit’s Ridinilazole Preserves Microbiome During Treatment of C. Difficile Infection
Jun 17, 2016 07:27AM Ayretrade, Inc. (SUMM) Announces Enrollment of First Patient in PhaseOut DMD
Jun 17, 2016 07:00AM First Patient Enrolled in Summit’s PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys With DMD
Jun 16, 2016 07:00AM Summit Therapeutics to Present at JMP Securities Life Sciences Conference
Jun 8, 2016 07:00AM Summit Therapeutics to Host Utrophin R&D Day 15 June 2016
Jun 2, 2016 07:00AM Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2016 and Operational Progress
May 31, 2016 07:00AM Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2016 on 2 June 2016
May 23, 2016 07:00AM Summit to Present Phase 2 CoDIFy Trial Data Highlighting Ridinilazole's Preservation of the Microbiome in CDI Patients at ASM Microbe 2016
May 10, 2016 07:00AM Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016
May 6, 2016 07:00AM Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016
Apr 28, 2016 07:25AM UPDATE: Summit Therapeutics (SMMT) Receives Additional Rdinilazole-Related U.S. Patent
Apr 28, 2016 07:00AM Summit Announces Further US Patent Granted for CDI Antibiotic Ridinilazole
Apr 26, 2016 07:00AM Summit’s IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid (SMT C1100), Into the US
View More Recent Stories View Older Stories